Nearly 600 teenagers ages 12 to 17 years who suffered an average of two to eight migraines per month participated in the trial, which consisted of a 12-week, single-blind, run-in phase followed by a 12-week, double-blind, treatment phase. In both phases, patients received either a placebo or one of three combinations: sumatriptan 10 mg/naproxen sodium 60 mg; sumatriptan 30 mg/naproxen 180 mg; or sumatriptan 85 mg/naproxen 500 mg.
The study found that all three doses were effective and well tolerated among patients. In particular, the 10/60-mg dose was more effective for shorter-duration headaches and younger teenagers, while the 85/500-mg dose proved more effective for recurring migraines and older teenagers.
Related Articles on Pain Management:New Treatment Uses IV Injections for Severe Migraines
CMS Proposed Cutoff of TENS Coverage Draws Scrutiny from Congressman
Hospira Recalls Opioid Cartridges